Immuno-chemo before surgery for thick or large stomach cancers
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of immunotherapy and chemotherapy given before surgery to shrink stomach cancers that are particularly thick or large. It aims to see if this approach can make these hard-to-treat tumors easier to remove and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stomach cancer that has not spread to other organs, and it is either a hard, thick-walled type (Type 4) or a large tumor bigger than 8 cm (large Type 3).
- You should be between 18 and 70 years old and in good enough health to get around (ECOG 0 or 1).
- Before starting, you need a surgery with a tiny camera to check that the cancer hasn't spread to the lining of your belly.
- Your blood counts and organ function (liver, kidneys, clotting) must be within a certain healthy range.
- You cannot have had any previous chemotherapy, radiation, or immunotherapy for this cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This Phase 2 trial studies giving tislelizumab (an immune therapy) together with pre-surgery chemoradiation for locally advanced stomach or GEJ (esophagus-stomach junction) adenocarcinoma. It compares this approach to the standard treatment (chemoradiation plus surgery) to see if it improves outcomes.
This trial is testing a combination of three medicines—an immunotherapy (anti-PD-1), an immune booster (thymalfasin), and a chemotherapy regimen (SOX)—given before surgery to shrink stage III stomach or gastroesophageal junction cancer and improve outcomes.
This trial tests a combination of four drugs given before surgery for stomach cancer that can be removed but is considered borderline resectable. The goal is to shrink the tumor to make surgery more successful and potentially improve outcomes.
This trial tests a combination of three drugs (envollizumab, fruquintinib, and chemotherapy) given before surgery, to see if it can shrink stomach cancer enough to make it removable. It compares this combination to chemotherapy alone.
This trial tests a combination of immune therapy and chemotherapy given before surgery for stomach or esophagus-stomach cancer. The goal is to shrink the tumor to make surgery more effective and possibly improve outcomes.
Hear when a new Stomach Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.